Polly Lebuhn, MD
Internal Medicine · Paducah, KYNPI 1417026949
Payments from drug & device makers
Across 133 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$346
- Novo Nordisk$336
- Ironshore Pharmaceuticals Inc.$279
- Pfizer$181
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$103
- Dexcom, Inc.$99
- plus $622 from 17 others
What the payments were for
- Food & beverage$1,95299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $346 |
| Novo Nordisk | 37 | $336 |
| Ironshore Pharmaceuticals Inc. | 6 | $279 |
| Pfizer | 11 | $181 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $103 |
| Dexcom, Inc. | 6 | $99 |
| AbbVie(2 entities) | 5 | $96 |
| Astellas Pharma US Inc | 5 | $77 |
| Exact Sciences | 4 | $73 |
| Lilly USA, LLC | 4 | $58 |
| GSK | 3 | $55 |
| Boehringer Ingelheim | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Amarin Pharma, Inc. | 2 | $28 |
| Bayer | 2 | $27 |
| Shire North American Group Inc | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,966 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $237,556 |
| EliquisApixaban | 186 | $164,312 |
| JardianceEmpagliflozin | 100 | $88,738 |
| XareltoRivaroxaban | 61 | $87,259 |
| TrulicityDulaglutide | 57 | $71,479 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $57,186 |
| MyrbetriqMirabegron | 60 | $42,805 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $42,668 |
| MounjaroTirzepatide | 20 | $38,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $38,387 |
| FarxigaDapagliflozin Propanediol | 25 | $26,862 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $19,698 |
| Repatha SyringeEvolocumab | 14 | $17,506 |
| Repatha SureclickEvolocumab | 21 | $14,194 |
| Praluent PenAlirocumab | 21 | $13,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $336 | $237,556137 claims |
| PfizerEliquis, Premarin, Toviaz | $181 | $176,661215 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $58 | $110,36177 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $39 | $94,078111 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $42,80560 claims |
| AbbVieNamzaric, Linzess, Synthroid | $96 | $41,319140 claims |
| GSKTrelegy Ellipta | $55 | $38,38735 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $19 | $4,00713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Paducah
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Ryan FrazinePaducah$38K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.